EpiCast Report: Acne - Epidemiology Forecast to 2022

LONDON, March 25, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

EpiCast Report: Acne - Epidemiology Forecast to 2022


EpiCast Report: Acne - Epidemiology Forecast to 2022

Summary

Acne vulgaris (acne) is an inflammatory skin disease that affects nearly all adolescents and adults at some point in their lives. The clinical presentation of acne ranges from a mild comedonal form to severe inflammatory cystic acne of the face, chest, and back. Globally, acne has a lifetime prevalence of over 90% in people of all ages, and a point-prevalence of approximately 85% in the population ages 15–24 years.

GlobalData's epidemiological analysis forecasts an increase in the total prevalent cases of acne in people ages 10–44 years in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK), from 103.91 million prevalent cases in 2012 to 105.46 million prevalent cases in 2022, with a decadal growth rate of 1.5%. As GlobalData epidemiologists used steady prevalence proportions of acne over the forecast period, the growth in prevalent cases in each market can be attributed to the change in population demographics in people ages 10–44 years in the respective markets.

Although acne is not a life-endangering condition, it is associated with a huge psychosocial impact and economic burden. GlobalData's epidemiological forecast emphasizes the need for preventive measures that are directed towards high-risk groups and signifies the need for early intervention with the available effective treatments in order to tackle the increasing burden of acne.

GlobalData epidemiologists forecast the prevalent cases of acne in the 6MM from 2012–2022 using nationally-representative, country-specific studies published in peer-reviewed journals that provided the age- and sex-specific prevalence of acne in the 6MM. Additionally, they further segmented the total prevalent cases of acne by severity. GlobalData epidemiologists ensured that the forecast methodology was consistent across all the 6MM to allow for a meaningful comparison of the total prevalent cases of acne across these markets.

Scope

- The Acne EpiCast Report provides an overview of the risk factors and global trends of acne in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of acne prevalent cases segmented by age (in five-year increments beginning at age 0 and ending at age 44 years), sex, and stage in these six markets.
- The acne epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global acne market.
- Quantify patient populations in the global acne market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for acne therapeutics in each of the markets covered.
- Identify the percentage of acne prevalent cases by stage.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 8
3.2.1 A family history of acne increases the risk of acne by four times 8
3.2.2 Diet is the most common aggravating factor of acne 9
3.2.3 The relationship between smoking and acne is unclear 10
3.2.4 Depression and anxiety are common comorbidities in acne patients 11
3.3 Global Trends 12
3.3.1 US 13
3.3.2 5EU 14
3.4 Forecast Methodology 16
3.4.1 Sources Used 17
3.4.2 Sources Not Used 20
3.5 Forecast Assumptions and Methods 21
3.5.1 US 21
3.5.2 France 22
3.5.3 Germany 22
3.5.4 Italy and Spain 23
3.5.5 UK 24
3.6 Epidemiology Forecast for Acne (2012–2022) 25
3.6.1 Total Prevalent Cases of Acne Vulgaris 25
3.6.2 Age-Specific Total Prevalent Cases of Acne Vulgaris 27
3.6.3 Sex-Specific Total Prevalent Cases of Acne Vulgaris 29
3.6.4 Age-Standardized Total Prevalence of Acne Vulgaris 31
3.6.5 Total Prevalent Cases of Acne Vulgaris by Severity 33
3.7 Discussion 35
3.7.1 Conclusions on Epidemiological Trends 35
3.7.2 Limitations of the Analysis 36
3.7.3 Strengths of the Analysis 37
4 Appendix 38
4.1 Bibliography 38
4.2 About the Authors 43
4.2.1 Epidemiologists 43
4.2.2 Reviewers 43
4.2.3 Global Director of Epidemiology and Health Policy 45
4.2.4 Global Head of Healthcare 45
4.3 About GlobalData 46
4.4 About EpiCast 46
4.5 Disclaimer 47
1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Acne 8
Table 2: Classification of Acne Severity 16
Table 3: 6MM, Sources of Acne Prevalence Data 17
Table 4: 6MM, Sources of Acne Severity Data 17
Table 5: 6MM, Total Prevalent Cases of Acne Vulgaris, Ages 10–44 years, Both Sexes, N (Millions), 2012–2022 26
Table 6: 6MM, Total Prevalent Cases of Acne Vulgaris, by Age, Both Sexes, N (Millions), (Row %), 2012 27
Table 7: 6MM, Total Prevalent Cases of Acne Vulgaris, by Sex, Ages 10–44 Years, N (Row %), 2012 29
Table 8: 6MM, Total Prevalent Cases of Acne Vulgaris by Severity, Ages 10–44 Years, Both Sexes, N (Millions) (Row %), 2012 33
1.2 List of Figures

Figure 1: 6MM, Total Prevalent Cases of Acne Vulgaris, Ages 10–44 years, Both Sexes, N (Millions), 2012–2022 26
Figure 2: 6MM, Total Prevalent Cases of Acne Vulgaris, by Age, Both Sexes, N (Millions), 2012 28
Figure 3: 6MM, Total Prevalent Cases of Acne Vulgaris, by Sex, Ages 10–44 Years, N (Millions), 2012 30
Figure 4: 6MM, Age-Standardized Total Prevalence of Acne Vulgaris, Ages 10–44 Years, 2012 32
Figure 5: 6MM, Total Prevalent Cases of Acne Vulgaris by Severity, Ages 10–44 Years, Both Sexes, N (Millions), 2012 34


Read the full report:
EpiCast Report: Acne - Epidemiology Forecast to 2022
http://www.reportbuyer.com/pharma_healthcare/diseases/epicast_report_acne_epidemiology_forecast_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer